Compare PLAB & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAB | AGIO |
|---|---|---|
| Founded | 1969 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1995 | 2013 |
| Metric | PLAB | AGIO |
|---|---|---|
| Price | $29.33 | $28.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $44.33 | $38.88 |
| AVG Volume (30 Days) | ★ 1.8M | 686.7K |
| Earning Date | 05-27-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.09 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $535,276,000.00 | $43,011,000.00 |
| Revenue This Year | $6.70 | $76.75 |
| Revenue Next Year | $4.96 | $170.73 |
| P/E Ratio | $42.59 | ★ N/A |
| Revenue Growth | ★ 18.77 | N/A |
| 52 Week Low | $18.04 | $22.24 |
| 52 Week High | $56.00 | $46.00 |
| Indicator | PLAB | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 27.17 | 49.15 |
| Support Level | $21.52 | $26.75 |
| Resistance Level | $38.00 | $29.49 |
| Average True Range (ATR) | 2.58 | 1.30 |
| MACD | -2.30 | 0.03 |
| Stochastic Oscillator | 0.22 | 44.13 |
Photronics Inc is a U.S.-based company principally engaged in the manufacturing of photomasks, which are high-precision photographic quartz or glass plates containing microscopic images of electronic circuits. Photomasks are a key element in the manufacture of integrated circuits (ICs) and flat-panel displays (FPDs) and are used as masters to transfer circuit patterns onto semiconductor wafers and FPD substrates during fabrication, as well as to a lesser extent, other types of electrical and optical components. The Company has manufacturing facilities in Taiwan, China, South Korea, the United States, and Europe, and generates revenue globally, with Taiwan contributing the majority of total revenue.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.